StockNews.AI
CVS
StockNews.AI
12 days

CVS Weight Management™ Program Improves Health Outcomes While Also Lowering Costs

1. CVS Weight Management program shows over 15% average weight loss. 2. 3.5 million members now have access to the program. 3. Clients adopting the program saved up to 26% on GLP-1 drug costs. 4. Satisfaction rate among participants reached 92% after six months. 5. Participants see significant improvements with combined medication and lifestyle support.

8 mins saved
Full Article

FAQ

Why Bullish?

The successful data from the Weight Management program suggests CVS's strong market position. Historical trends show improved services can lead to stock price increases.

How important is it?

The article outlines measurable success in a major program that directly enhances CVS's value proposition in the healthcare market.

Why Long Term?

The program aims for sustainable health outcomes, which can improve revenues steadily over time, similar to the outcomes following successful health initiatives.

Related Companies

Three and a Half Million Members of CVS Caremark's Clients Now Enjoy Access to Clinical Weight Loss Program With Proven Results, High Satisfaction , /PRNewswire/ -- CVS Health® (NYSE: CVS) released compelling data today from the CVS Weight ManagementTM  program in which participants achieved more than 15% weight loss on average, including existing anti-obesity medication users who succeeded in nearly doubling their pre-program weight loss while working with program clinicians on diet and lifestyle.1 Before enrolling in the CVS Weight Management program, 70% of members were using a weight management drug without any lifestyle or nutrition support.1 The initial results demonstrate improved weight loss and high program satisfaction for CVS Caremark clients' plan members trying a lifestyle-first approach and additional clinical effectiveness and cost savings for members receiving clinical support while taking weight management medications like GLP-1s. The CVS Weight Management program provides one-on-one support from a dedicated registered dietitian in a virtual setting, including personalized nutrition planning based on health needs, social determinants of health, and cultural and individual preferences, empowering members to develop sustainable habits for achieving long-term weight loss.  At the direction of plan sponsors, the program can seamlessly integrate into a member's existing pharmacy benefit. "The data are clear: GLP-1 weight-loss drugs work best when combined with nutrition, lifestyle support and proper dosing2," said Dr. Michelle Gourdine, Chief Medical Officer, CVS Caremark. "The CVS Weight Management program is a clinically rigorous solution that helps optimize the effectiveness of GLP-1s for weight loss for those that use them. It also supports members in making changes to improve weight and cardiometabolic health without medication to help offset or achieve success without the use of medication." CVS Caremark Clients Experience Significant Cost SavingsCVS Caremark clients who adopted the CVS Weight Management program spent up to 26% less on GLP-1 medications for weight-loss, compared to those clients who did not adopt the program.1 The program is also leaving a lasting impact, with 92% of participating plan members expressing satisfaction after six months in the program.1 These findings are especially compelling when the list price of GLP-1 drugs, which are set by the drug manufacturers, can easily cost thousands of dollars per year per member. As of February 1, 2025, the CVS Weight Management program is now available to more than 3.5 million CVS Caremark plan members. The influx in enrollment nods to proven results in a program that is optimizing the effectiveness of GLP-1 weight loss drugs while lowering overall plan pharmacy costs.  In clinical trials, GLP-1 anti-obesity medications showed the best outcomes when drug therapy was combined with structured lifestyle support,2 such as those embedded in the CVS Weight Management program. Data Demonstrates Durable, Lifestyle-First Solutions for Sustainable Health OutcomesDespite FDA prescription drug labeling recommendations to take GLP-1's in combination with diet and physical activity, before enrolling in the CVS Weight Management program, 70% of members were using a weight management drug without any lifestyle or nutrition support.1 After completing the program, the clinical results for members are particularly striking:   Before program enrollment nearly 30% of members had lost less than 1 percent body weight on anti-obesity medication. These same members lost on average 11.7% of body weight after enrollment. That's 13x increase in total weight loss.1 The program accelerated weight-loss and delivered best-in-class results of average 20% weight loss for those with moderate success prior to enrollment.1 Members who chose to discontinue anti-obesity medication and retain lifestyle support maintained 94% of their weight loss after 6 months.1   Results are derived from a population of 265,000 members from 2023-2024.  About CVS HealthCVS Health® is the leading health solutions company, delivering care like no one else can. We reach more people and improve the health of communities across America through our local presence, digital channels and over 300,000 dedicated colleagues — including more than 40,000 physicians, pharmacists, nurses and nurse practitioners. Wherever and whenever people need us, we help them with their health — whether that's managing chronic diseases, staying compliant with their medications or accessing affordable health and wellness services in the most convenient ways. We help people navigate the health care system — and their personal health care — by improving access, lowering costs and being a trusted partner for every meaningful moment of health. And we do it all with heart, each and every day. Follow @CVSHealth on social media. Media contactPhil Blando202-258-4978[email protected]  1 CVS Health Analytics, 2024. Weight Management Results. Data from August 2023 through September 2024. 265K Total Covered Lives, as of 9/30/24. 2 Wilding, J. P., et al  (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/nejmoa2032183 SOURCE CVS Health WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News